Changes in laboratory results in transgender individuals on hormone therapy - a retrospective study and practical approach.

Autor:	Boekhout-Berends ET; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Chemistry, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands., Wiepjes CM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Division of Endocrinology, Center of Expertise on Gender Dysphoria, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands., Nota NM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Division of Endocrinology, Center of Expertise on Gender Dysphoria, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands., Schotman HH; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Chemistry, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands., Heijboer AC; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam Gastroenterology Endocrinology & Metabolism, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.; Amsterdam UMC, University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam Gastroenterology Endocrinology & Metabolism, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands., den Heijer M; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Division of Endocrinology, Center of Expertise on Gender Dysphoria, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Jazyk:	angličtina
Zdroj:	European journal of endocrinology [Eur J Endocrinol] 2023 May 24. Date of Electronic Publication: 2023 May 24.
DOI:	10.1093/ejendo/lvad052
Abstrakt:	Objective: Interpreting laboratory results for transgender individuals who started hormone therapy requires careful consideration, specifically for analytes that have sex-specific reference intervals. In literature, conflicting data exist on the effect of hormone therapy on laboratory parameters. By studying a large cohort, we aim to define what reference category (male or female) is most appropriate to use for the transgender population over the course of gender-affirming therapy. Methods: A total of 2201 people (1178 transgender women and 1023 transgender men) were included in this study. We analyzed hemoglobin (Hb), hematocrit (Ht), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), creatinine, and prolactin, at three different time points: pretreatment, during hormone therapy, and after gonadectomy. Results: For transgender women, Hb and Ht levels decrease after initiation of hormone therapy. The concentration of liver enzymes ALT, AST, and ALP decrease whereas the levels of GGT do not change statistically significantly. Creatinine levels decrease whereas prolactin levels rise in transgender women during gender-affirming therapy. For transgender men Hb and Ht values increase after starting hormone therapy. Liver enzymes and creatinine levels increase statistically significant as well upon hormone therapy while prolactin concentrations decrease. Overall, reference intervals in transgender people after 1 year on hormone therapy resembled those of their affirmed gender. Conclusions: Generating transgender-specific reference intervals is not essential to correctly interpret laboratory results. As a practical approach, we recommend to use the reference intervals of the affirmed gender from 1 year onwards after starting hormone therapy. (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu